

Supplementary materials

Yarden Golan, Ph.D., Mary Prah, M.D., Arianna Cassidy, M.D., Alan H.B. Wu, Ph.D., Unurzul Jigmeddagva, M.D., Christine Y. Lin, Veronica J. Gonzalez, M.D, Emilia Basilio, M.D, M.P.H, Lakshmi Warriar, Sirirak Buarpung, D.V.M., Ph.D., Ifeyinwa V. Asiodu, Ph.D, R.N., Nadav Ahituv, Ph.D., Valerie J. Flaherman, M.D., M.P.H., Stephanie L. Gaw, M.D., Ph.D

Milk samples- Fresh human milk samples were self-collected by participants before first vaccine dose, at the day of second dose and 4 weeks post second dose. Serial samples were self-collected once a week. If not collected immediately by the study staff, mothers were instructed to freeze milk in their home freezer as soon as possible after pumping and bring with them to their next study visit. Samples were kept on ice until arriving in the lab for processing. Milk was aliquoted and stored in -80°C until analysed. We acknowledge that not all lactating individuals use terms or language such as mother, breastfeeding, and breast milk to describe their infant feeding practices¹. Data were reported according to language used on the study materials.

SARS-CoV-2 Breast milk IgA ELISA- After thawing, milk fat was separated by cold centrifugation at 10,000g for 10 min. RayBio® COVID-19 S1 RBD protein Human IgA ELISA Kit (Catalog #: IEQ-CoVS1RBD-IgA) was used. Breast milk supernatant was diluted in 1:1 ratio with samples dilutant buffer (RayBiotech, GA, USA). Samples were plated in duplicate on a 96-well plate containing S1 Spike protein RBD, and samples were also plated in duplicate on a second plate 96-well plate containing human albumin to account for non-specific binding. Both plates contain seven S1 Spike Protein RBD standards and one blank negative control. Plates loaded with samples were incubated over night at 4°C and were developed the day after using the manufacturer's protocol. The mean absorbance of each sample was captured on an ELISA plate reader at 450

nm, and background subtracted from human albumin. Standard controls were used to create a standard curve and determine the level of anti-SARS-CoV-2 S1 RBD protein IgA in unit/ml. A sample was considered positive if greater than 21.4 unit/mL, and negative if less than 21.4 unit/mL. In case of false positive, pre-vaccine sample that was positive for antibodies, the sample was run again on a separate experiment to verify results.

Plasma samples- Plasma was isolated from whole blood by centrifugation and immediately cryopreserved.

SARS-CoV-2 plasma serology. Anti-SARS-CoV-2 plasma IgM and IgG antibodies were measured using the Pylon 3D automated immunoassay system (ET Healthcare, Palo Alto, CA) in the Zuckerberg San Francisco General Hospital Clinical Laboratory under a validated research protocol. In brief, quartz glass probes are pre-coated with either affinity purified goat anti Human IgM (IgM capture) or Protein G (IgG capture) are dipped into diluted patient sample. Samples are washed, and then the probe is dipped into the assay reagent containing both biotinylated recombinant spike protein receptor binding domain (RBD) and nucleocapsid protein (NP). After a washing, the probe is incubated with a Cy5-streptavidin (Cy5-SA) polysaccharide conjugate reagent, allowing for cyclic amplification of the fluorescence signal. The background corrected signal is reported as relative fluorescent units (RFU) which is proportional to the amount of specific antibodies in the sample allowing for quantification. Levels of IgM and IgG were considered positive if greater than 50 RFU.

1. MacDonald T, Noel-Weiss J, West D, et al. Transmasculine individuals' experiences with lactation, chestfeeding, and gender identity: A qualitative study. *BMC Pregnancy Childbirth*. 2016;16(1):106. doi:10.1186/s12884-016-0907-y